Incomplete expansion and fracture of the stent associated with insufficient antiplatelet therapy produced in-stent thrombosis. Collateral flow prevented kidney necrosis.

We aimed to compare regimens including calcium channel blockers (CCBs) to non-CCBs agents such as angiotensinconverting enzyme inhibitors (ACEIs) and/or angiotensin receptor blockers (ARBs) regarding progression in nondiabetic chronic kidney disease (CKD). There was no difference in reaching serum creatinine concentration (Cr) to more than 7 mg/dL and/or commencing dialysis. The CCB group compared to non-CCBs displayed a higher mean Cr (as well as a higher rate of increase) and proteinuria. Medication with CCBs and younger age were associated with adverse renal function outcome. It is concluded that CCBs are less effective than ACEIs or ARBs on preserving renal function and ameliorating proteinuria in nondiabetic CKD.

No abstract